Basic Information


GTO ID GTC0923
Trial ID ChiCTR2100044497
Disease Nasopharyngeal Disease | Lymphoma
Altered gene EBV
Therapeutic/Target gene Target gene
TherapyCAR-T cell|TCR-T cell
Treatment EBV CAR-T cells|EBV TCR-T cells
HLAHLA-A*11:01|HLA-A*02:01|HLA-A*24:02
PhaseEarly_Phase1
Recruitment statusRecruiting
TitleClinical study of safety and preliminary efficacy of EBV CAR-T/TCR-T cells in patients with relapsed/refractory EBV positive lymphoma/nasopharyngeal carcinoma
Year2021
CountryChina
Company sponsorThe First Affiliated Hospital of Zhengzhou University

Clinical Result

Cohort1: dose level 1
Administration route infusion
Dosage 3E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Cohort2: dose level 2
Administration route infusion
Dosage 9E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Cohort3: dose level 3
Administration route infusion
Dosage 2.7E7 cells/kg
Donor type autologous
Age Adult, Older_Adult
Cohort4: dose level 4
Administration route infusion
Dosage 5E6 cells/kg
Donor type autologous
Age Adult, Older_Adult
Cohort5: dose level 5
Administration route infusion
Dosage 1.5E7 cells/kg
Donor type autologous
Age Adult, Older_Adult
Cohort6: dose level 6
Administration route infusion
Dosage 4.5E7 cells/kg
Donor type autologous
Age Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph